India, Aug. 4 -- CervoMed Inc. (CRVO), a clinical-stage biotechnology company, on Tuesday reported that its drug candidate Neflamapimod has received an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP) for development in treating Dementia with Lewy Bodies.
With the passport, the company may subsequently gain guidance from the Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and various health technology assessment (HTA) bodies, including the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Therapeutics and Toxicology Centre (AWTTC), and the Department of Health of Northern Ireland.
Dementia with L...